Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide co-administration effects on cabazitaxel exposure in metastatic castration-resistant prostate cancer
NL-OMON36037Active, not recruiting
- Sponsor
- Medical Oncology
- Start
- May 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cabazitaxel and budesonide in prostate cancer (PCa), sponsored by Medical Oncology. Started May 2011; status: active, not recruiting.
02
Drugs
cabazitaxelbudesonide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON36037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36037.